SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Docetaxel summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001107/WC500073419.pdf (last accessed 30 November 2010).
  • 2
    Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 1993; 17: 30513.
  • 3
    Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer 2007; 7: 197.
  • 4
    Bruno R, Hille D, Riva A, Vivier N, ten Bokkel H, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 18796.
  • 5
    Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75: 44854.
  • 6
    Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001; 19: 11606.
  • 7
    Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010; 69: 46574.
  • 8
    Koolen SL, Beijnen JH, Schellens JH. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin Pharmacol Ther 2010; 87: 1269.
  • 9
    van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 2009; 69: 89969002.
  • 10
    Docetaxel label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf (last accessed 10 January 2011).
  • 11
    Zufia López L, Aldaz Pastor A, Aramendia Beitia JM, Arrobas Velilla J, Giraldez Deiró J. Determination of docetaxel and paclitaxel in human plasma by high performance liquid chromatography. Validation and application to clinical pharmacokinetic studies. Ther Drug Monit 2006; 28: 199205.
  • 12
    Beal SL, Sheiner LB. NONMEM Users Guides. Hanover, MD: GloboMax, LLC, 1992.
  • 13
    Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 15372.
  • 14
    Baille P, Bruno R, Schellens JHM, Webster LK, Millward M, Verweij J, Montay G. Optimal sampling strategies for Bayesian estimation of docetaxel clearance. Clin Cancer Res 1997; 3: 15358.
  • 15
    Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481504.
  • 16
    Baker SD, Zhao M, Ck L, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004; 10: 197683.
  • 17
    McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998; 42: 1559.
  • 18
    Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006; 45: 23552.
  • 19
    Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 12558.
  • 20
    Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68: 67787.
  • 21
    Engels FK, Loos WJ, van der Bol JM, de Brujin P, Mathijssen RHJ, Verweij J, Mathot RAA. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 2011; 17: 35362.
  • 22
    Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, Greenberg HE. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 8319.
  • 23
    Lim YW, Goh BC, Wang LZ, Tan SH, Chuah BY, Lim SE, Iau P, Buhari SA, Chan CW, Sukri NB, Cordero MT, Soo R, Lee SC. Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. Ann Oncol 2010; 21: 217582.
  • 24
    Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 2005; 23: 41321.